Inclusion Criteria:

          -  Histological/cytological diagnosis of selected locally advanced or metastatic solid
             tumor

          -  Demonstrated radiographic progression on most recent tumor assessment imaging

          -  Have ≥1 measurable lesion as defined by RECIST 1.1 that has not been previously
             irradiated

          -  Eastern Cooperative Oncology Group performance status 0-2 for Part 1 and 0-1 for Part
             2

          -  Adequate hematologic, renal, liver, and coagulation functions

          -  LVEF ≥50% by echocardiogram or MUGA

          -  Resolved acute effects of any prior therapy

          -  Participants in Dose Expansion (Part 2) must have ≥2 prior lines of standard of care
             therapy

          -  Able to provide tumor tissue for submission to the Sponsor, including mandatory
             pre-treatment tumor biopsy (adequate archival tissue within the past 1 year is
             accepted in lieu of new biopsy) for all participants. Participants in Part 2 must also
             be able to undergo new (de novo) tumor biopsy at baseline (pre-treatment) and
             on-treatment biopsy until the Sponsor deems that an adequate number of biopsied
             samples have been received.

        Exclusion Criteria:

          -  Known active symptomatic brain or leptomeningeal metastases requiring steroids.

          -  Other active malignancy within 3 years prior to enrollment, except for adequately
             treated basal cell or squamous cell skin cancer, or carcinoma in situ

          -  Major surgery or radiation therapy within 4 weeks prior to planned first dose

          -  Last systemic anti-cancer therapy within 4 weeks prior to planned first dose (6 weeks
             for mitomycin C or nitrosoureas). Participants who received anti-PD-1 therapy require
             an interval of 90 days prior to first dose

          -  Participation in other studies involving investigational drug(s) within 4 weeks prior
             to planned first dose

          -  Active and clinically significant bacterial, fungal, or viral infection; Hepatitis B
             or Hepatitis C infection, AIDS-related illness (HIV+ and in good immune health as
             defined in the protocol may be eligible)

          -  Active COVID-19/SARS-CoV2

          -  Anticoagulation with vitamin K antagonists is not allowed

          -  Active bleeding disorder in the past 6 months prior to first dose

          -  History of clinically significant severe immune mediated adverse event that was
             considered related to prior immune modulatory therapy and required immunosuppressive
             therapy (other than hormone replacement therapy)

          -  History of interstitial lung disease or pneumonitis

          -  Organ transplant requiring immunosuppressive treatment or prior allogeneic bone marrow
             or hematopoietic stem cell transplant

          -  Pregnant or breastfeeding female participant